Bollard Group’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Bollard Group’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,009	Closed	-$7K	–	429
2022 Q1	$7K	Hold	1,009	–	–	﹤0.01%	412
2021 Q4	$8K	Hold	1,009	–	–	﹤0.01%	417
2021 Q3	$7K	Hold	1,009	–	–	﹤0.01%	413
2021 Q2	$7K	Hold	1,009	–	–	﹤0.01%	411
2021 Q1	$10K	Hold	1,009	–	–	﹤0.01%	412
2020 Q4	$7K	Hold	1,009	–	–	﹤0.01%	413
2020 Q3	$8K	Sell	1,009 -3,186	-76%	-$19.8K	﹤0.01%	413
2020 Q2	$29K	Buy	+4,195	New	+$22.6K	﹤0.01%	391

Other funds holding JNCE

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

Bollard Group's JNCE Position: Q2 2022 in Review

Bollard Group sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2022, closing a stake of 1,009 shares — an estimated $7K sold.

Bollard Group first reported a position in JNCE in Q2 2020 and held it in 8 quarters. The position peaked at $29K in Q2 2020. 102 funds tracked by Wall St. Rank hold JNCE as of Q2 2022.

Bollard Group reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Bollard Group sold 1,009 Jounce Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $7K.
Bollard Group first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2020 and held it in 8 quarters.
Bollard Group's Jounce Therapeutics, Inc. Common Stock position peaked at $29K in Q2 2020.
102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Bollard Group's 13F filing for Q2 2022, filed 12 Aug 2022.